Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Hyperprogressive disease of non-small-cell lung adenocarcinoma under immune-checkpoint inhibitors: A new response pattern to be recognized by the radiologist.

Ferretti GR, Giaj Levra M, Jankowski A, Toffart AC, Moro Sibilot D.

Diagn Interv Imaging. 2019 Feb 7. pii: S2211-5684(19)30002-6. doi: 10.1016/j.diii.2018.12.004. [Epub ahead of print] No abstract available.

PMID:
30745041
2.

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.

Br J Cancer. 2019 Feb;120(4):387-397. doi: 10.1038/s41416-019-0379-8. Epub 2019 Feb 11.

PMID:
30739911
3.

A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.

Pujol JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, Uwer L, Hureaux J, Guisier F, Carmier D, Madelaine J, Otto J, Gounant V, Merle P, Mourlanette P, Molinier O, Renault A, Rabeau A, Antoine M, Denis MG, Bommart S, Langlais A, Morin F, Souquet PJ.

J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30025-5. doi: 10.1016/j.jtho.2019.01.008. [Epub ahead of print]

PMID:
30664989
4.

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup.

Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Erratum in: Lancet Oncol. 2019 Mar;20(3):e132.

PMID:
30660609
5.

Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.

von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, Hida T, Moro-Sibilot D, Conkling P, Gandara DR, Rittmeyer A, Gandhi M, Yu W, Matheny C, Patel H, Sandler A, Ballinger M, Kowanetz M, Park K.

Eur J Cancer. 2019 Jan;107:124-132. doi: 10.1016/j.ejca.2018.11.020. Epub 2018 Dec 17.

PMID:
30562710
6.

[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer].

Mignard X, Antoine M, Moro-Sibilot D, Dayen C, Mennecier B, Gervais R, Amour E, Milleron B, Morin F, Zalcman G, Wislez M.

Rev Mal Respir. 2018 Nov;35(9):983-988. doi: 10.1016/j.rmr.2018.08.006. Epub 2018 Sep 20. French.

PMID:
30243521
7.

A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics.

Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, Chiari R, Westeel V, Poudenx M, Letreut J, Gervais R, Osman G, Girard N, Toffart AC, Novello S, Moro-Sibilot D.

J Thorac Oncol. 2019 Jan;14(1):130-134. doi: 10.1016/j.jtho.2018.08.2028. Epub 2018 Sep 11.

PMID:
30217489
8.

VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop.

Boudria A, Abou Faycal C, Jia T, Gout S, Keramidas M, Didier C, Lemaître N, Manet S, Coll JL, Toffart AC, Moro-Sibilot D, Albiges-Rizo C, Josserand V, Faurobert E, Brambilla C, Brambilla E, Gazzeri S, Eymin B.

Oncogene. 2019 Feb;38(7):1050-1066. doi: 10.1038/s41388-018-0486-7. Epub 2018 Sep 7.

PMID:
30194450
9.

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.

Mignard X, Ruppert AM, Antoine M, Vasseur J, Girard N, Mazières J, Moro-Sibilot D, Fallet V, Rabbe N, Thivolet-Bejui F, Rouquette I, Lantuejoul S, Cortot A, Saffroy R, Cadranel J, Lemoine A, Wislez M.

J Thorac Oncol. 2018 Dec;13(12):1962-1967. doi: 10.1016/j.jtho.2018.08.008. Epub 2018 Aug 24.

PMID:
30149144
10.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; IMpower150 Study Group.

N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.

11.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.

PMID:
29545318
12.

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, Maas L, Müller C, Dahmen I, Delhomme TM, Ardin M, Leblay N, Byrnes G, Sun R, De Reynies A, McLeer-Florin A, Bosco G, Malchers F, Menon R, Altmüller J, Becker C, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soloway MG, Wilkerson MD, Cun Y, McKay JD, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Lemaitre N, Soltermann A, Weder W, Tischler V, Brustugun OT, Lund-Iversen M, Helland Å, Solberg S, Ansén S, Wright G, Solomon B, Roz L, Pastorino U, Petersen I, Clement JH, Sänger J, Wolf J, Vingron M, Zander T, Perner S, Travis WD, Haas SA, Olivier M, Foll M, Büttner R, Hayes DN, Brambilla E, Fernandez-Cuesta L, Thomas RK.

Nat Commun. 2018 Mar 13;9(1):1048. doi: 10.1038/s41467-018-03099-x.

13.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.

14.

ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.

McLeer-Florin A, Duruisseaux M, Pinsolle J, Dubourd S, Mondet J, Phillips Houlbracq M, Magnat N, Fauré J, Chatagnon A, de Fraipont F, Giaj Levra M, Toffart AC, Ferretti G, Hainaut P, Brambilla E, Moro-Sibilot D, Lantuejoul S.

Lung Cancer. 2018 Feb;116:15-24. doi: 10.1016/j.lungcan.2017.12.004. Epub 2017 Dec 8.

PMID:
29413046
15.

Operation and Chemotherapy: Prognostic Factors for Lung Cancer With One Synchronous Metastasis.

Toffart AC, Duruisseaux M, Brichon PY, Pirvu A, Villa J, Selek L, Guillem P, Dumas I, Ferrer L, Levra MG, Moro-Sibilot D.

Ann Thorac Surg. 2018 Mar;105(3):957-965. doi: 10.1016/j.athoracsur.2017.10.040. Epub 2018 Feb 15.

PMID:
29397931
16.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Giroux Leprieur E, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB.

Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1.

17.

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.

Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, Pérol M.

Lung Cancer. 2017 Oct;112:181-187. doi: 10.1016/j.lungcan.2017.07.038. Epub 2017 Aug 5.

18.

Association between lung cancer somatic mutations and occupational exposure in never-smokers.

Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S; BioCAST/IFCT-1002 study investigators; to the BioCAST/IFCT- 1002 study.

Eur Respir J. 2017 Oct 26;50(4). pii: 1700716. doi: 10.1183/13993003.00716-2017. Print 2017 Oct.

PMID:
29074543
19.

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program.

Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranel J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT).

Ann Oncol. 2017 Nov 1;28(11):2715-2724. doi: 10.1093/annonc/mdx404.

PMID:
28945865
20.

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.

Sakhri L, Pinsolle J, Moro-Sibilot D, Pluchart H.

J Med Case Rep. 2017 Sep 16;11(1):262. doi: 10.1186/s13256-017-1436-7.

21.

EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.

Tomasini P, Brosseau S, Mazières J, Merlio JP, Beau-Faller M, Mosser J, Wislez M, Ouafik L, Besse B, Rouquette I, Debieuvre D, Escande F, Westeel V, Audigier-Valette C, Missy P, Langlais A, Morin F, Moro-Sibilot D, Zalcman G, Barlesi F.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700514. doi: 10.1183/13993003.00514-2017. Print 2017 Aug.

22.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700050. doi: 10.1183/13993003.00050-2017. Print 2017 Aug. Erratum in: Eur Respir J. 2017 Nov 9;50(5):.

23.

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.

Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G.

J Thorac Oncol. 2017 Oct;12(10):1496-1502. doi: 10.1016/j.jtho.2017.07.013. Epub 2017 Jul 24.

24.

[Clinical research activity of the French cancer cooperative network: Overview and perspectives].

Dubois C, Morin F, Moro-Sibilot D, Langlais A, Seitz JF, Girault C, Salles G, Haioun C, Deschaseaux P, Casassus P, Mathiot C, Pujade-Lauraine É, Votan B, Louvet C, Delpeut C, Bardet É, Vintonenko N, Hoang Xuan K, Vo M, Michon J, Milleron B.

Bull Cancer. 2017 Jul - Aug;104(7-8):652-661. doi: 10.1016/j.bulcan.2017.05.006. Epub 2017 Jul 5. French.

PMID:
28688747
25.

Partial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report.

Pluchart H, Pinsolle J, Cohen J, Ferretti GR, Bedouch P, Giaj Levra M, Toffart AC, Moro-Sibilot D.

J Med Case Rep. 2017 Jul 6;11(1):183. doi: 10.1186/s13256-017-1334-z.

26.

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.

Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D.

Oncotarget. 2017 Mar 28;8(13):21903-21917. doi: 10.18632/oncotarget.15746.

27.

Are ALK rearrangement variants promising predictive biomarker of ALK tyrosine kinase inhibitors efficacy?

Duruisseaux M, Mc Leer-Florin A, Moro-Sibilot D, Cadranel J.

Ann Oncol. 2017 Jun 1;28(6):1401. doi: 10.1093/annonc/mdx116. No abstract available.

PMID:
28368436
28.

Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.

Besse B, Mazières J, Ribassin-Majed L, Barlesi F, Bennouna J, Gervais R, Moreau L, Berard H, Debieuvre D, Molinier O, Moro-Sibilot D, Souquet PJ, Jacquot S, Petit L, Lena H, Pignon JP, Lacas B, Morin F, Milleron B, Zalcman G, Soria JC; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Ann Oncol. 2017 May 1;28(5):1078-1083. doi: 10.1093/annonc/mdx070.

PMID:
28327934
29.

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.

Guibert N, Barlesi F, Descourt R, Léna H, Besse B, Beau-Faller M, Mosser J, Pichon E, Merlio JP, Ouafik L, Guichard F, Mastroianni B, Moreau L, Wdowik A, Sabourin JC, Lemoine A, Missy P, Langlais A, Moro-Sibilot D, Mazières J.

J Thorac Oncol. 2017 Jun;12(6):963-973. doi: 10.1016/j.jtho.2017.02.001. Epub 2017 Feb 9.

30.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, Geater SL, Orlov S, Cortinovis D, Yu CJ, Hochmair M, Cortot AB, Tsai CM, Moro-Sibilot D, Campelo RG, McCulloch T, Sen P, Dugan M, Pantano S, Branle F, Massacesi C, de Castro G Jr.

Lancet. 2017 Mar 4;389(10072):917-929. doi: 10.1016/S0140-6736(17)30123-X. Epub 2017 Jan 24. Erratum in: Lancet. 2017 Mar 4;389(10072):908.

PMID:
28126333
31.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.

Levallet G, Dubois F, Fouret P, Antoine M, Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E, Debieuvre D, Molinier O, Galateau-Sallé F, Mazieres J, Quoix E, Pujol JL, Moro-Sibilot D, Langlais A, Morin F, Westeel V, Zalcman G.

Oncotarget. 2017 Jan 17;8(3):4313-4329. doi: 10.18632/oncotarget.14025.

32.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI.

J Clin Oncol. 2016 Dec;34(34):4079-4085. Epub 2016 Oct 31.

PMID:
27863201
33.

Routine molecular profiling of patients with NSCLC - Authors' reply.

Mazières J, Merlio JP, Missy P, Moro-Sibilot D, Barlesi F.

Lancet. 2016 Sep 10;388(10049):1054-1055. doi: 10.1016/S0140-6736(16)31136-9. No abstract available.

PMID:
27628516
34.

Nivolumab dans le traitement des CBNPC.

Moro-Sibilot D, Ferrer L, Levra MG, Toffart AC.

Bull Cancer. 2016 Jun;103(6 Suppl 1):S12-5. doi: 10.1016/S0007-4551(16)30141-2. Review. French.

PMID:
27494968
35.

Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer--Letter.

Cortot AB, Moro-Sibilot D, Cadranel J.

Clin Cancer Res. 2016 Apr 1;22(7):1827. doi: 10.1158/1078-0432.CCR-15-2824. No abstract available.

36.

Personalized chemotherapy of lung cancer: What the radiologist should know.

Ferretti GR, Reymond E, Delouche A, Sakhri L, Jankowski A, Moro-Sibilot D, Lantuejoul S, Toffart AC.

Diagn Interv Imaging. 2016 Mar;97(3):287-96. doi: 10.1016/j.diii.2015.11.013. Epub 2016 Feb 5. Review.

37.

Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.

Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts JG, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, Girvan A, Visseren-Grul C, Schnabel PA.

Lung Cancer. 2015 Dec;90(3):427-32. doi: 10.1016/j.lungcan.2015.11.011. Epub 2015 Nov 10.

PMID:
26791802
38.

Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.

Smit E, Moro-Sibilot D, Carpeño Jde C, Lesniewski-Kmak K, Aerts J, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, Girvan A, Visseren-Grul C, Schnabel PA.

Lung Cancer. 2016 Feb;92:35-40. doi: 10.1016/j.lungcan.2015.11.022. Epub 2015 Dec 3.

PMID:
26775594
39.

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT).

Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24.

PMID:
26719230
40.

Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients.

Fiteni F, Vernerey D, Bonnetain F, Vaylet F, Sennélart H, Trédaniel J, Moro-Sibilot D, Herman D, Laizé H, Masson P, Derollez M, Clément-Duchêne C, Milleron B, Morin F, Zalcman G, Quoix E, Westeel V.

Eur J Cancer. 2016 Jan;52:120-8. doi: 10.1016/j.ejca.2015.10.004. Epub 2015 Dec 10.

PMID:
26682871
41.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.

J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23.

PMID:
26598747
42.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O.

Ann Oncol. 2016 Feb;27(2):281-6. doi: 10.1093/annonc/mdv573. Epub 2015 Nov 23.

PMID:
26598547
43.

Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.

Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, Pérol M, Zavadil J, Brambilla C, Olivier M, Couraud S.

Eur Respir J. 2015 Dec;46(6):1773-80. doi: 10.1183/13993003.00676-2015. Epub 2015 Oct 22.

44.

Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.

Cadranel J, Gervais R, Merle P, Moro-Sibilot D, Westeel V, Bigay-Game L, Quoix E, Friard S, Barlesi F, Lethrosne C, Moreau L, Monnet I, Salaun M, Oliviero G, Souquet PJ, Antoine M, Langlais A, Morin F, Wislez M, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT).

Eur Respir J. 2015 Nov;46(5):1440-50. doi: 10.1183/13993003.02358-2014. Epub 2015 Sep 17.

45.

Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).

Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavolé A, Mazières J, Toffart AC, Langlais A, Morin F, Zalcman G.

Lung Cancer. 2015 Aug;89(2):139-45. doi: 10.1016/j.lungcan.2015.05.016. Epub 2015 May 27.

PMID:
26059274
46.

High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets.

Fallet V, Saffroy R, Girard N, Mazieres J, Lantuejoul S, Vieira T, Rouquette I, Thivolet-Bejui F, Ung M, Poulot V, Schlick L, Moro-Sibilot D, Antoine M, Cadranel J, Lemoine A, Wislez M.

Ann Oncol. 2015 Aug;26(8):1748-53. doi: 10.1093/annonc/mdv232. Epub 2015 May 12.

PMID:
25969368
47.

Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.

Moro-Sibilot D, Smit E, de Castro Carpeño J, Lesniewski-Kmak K, Aerts J, Villatoro R, Kraaij K, Nacerddine K, Dyachkova Y, Smith KT, Taipale K, Girvan AC, Visseren-Grul C, Schnabel PA.

Lung Cancer. 2015 May;88(2):215-22. doi: 10.1016/j.lungcan.2015.02.011. Epub 2015 Feb 21.

PMID:
25748103
48.

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).

Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF.

J Geriatr Oncol. 2015 May;6(3):233-40. doi: 10.1016/j.jgo.2015.02.002. Epub 2015 Feb 16.

PMID:
25698450
49.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

Pujol JL, Lavole A, Quoix E, Molinier O, Souquet PJ, Barlesi F, Le Caer H, Moro-Sibilot D, Fournel P, Oster JP, Chatellain P, Barre P, Jeannin G, Mourlanette P, Derollez M, Herman D, Renault A, Dayen C, Lamy PJ, Langlais A, Morin F, Zalcman G; French Cooperative Thoracic Intergroup (IFCT); French Cooperative Thoracic Intergroup IFCT.

Ann Oncol. 2015 May;26(5):908-14. doi: 10.1093/annonc/mdv065. Epub 2015 Feb 16.

PMID:
25688059
50.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.

Couraud S, Souquet PJ, Paris C, Dô P, Doubre H, Pichon E, Dixmier A, Monnet I, Etienne-Mastroianni B, Vincent M, Trédaniel J, Perrichon M, Foucher P, Coudert B, Moro-Sibilot D, Dansin E, Labonne S, Missy P, Morin F, Blanché H, Zalcman G; French Cooperative Intergroup IFCT.

Eur Respir J. 2015 May;45(5):1403-14. doi: 10.1183/09031936.00097214. Epub 2015 Feb 5.

Supplemental Content

Loading ...
Support Center